MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 555530 | Name: PrCP-7414

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PrCP-7414, also known as PrCP inhibitor with CAS#1252037-41-4, is a potent PrCP inhibitor. For the convenience of communication, it is named as PrCP-7414. The last four digit of its CAS# was used for name.

Chemical Structure

PrCP-7414
CAS#1252037-41-4

Theoretical Analysis

MedKoo Cat#: 555530

Name: PrCP-7414

CAS#: 1252037-41-4

Chemical Formula: C31H33Cl2N5O2

Exact Mass: 577.2011

Molecular Weight: 578.54

Elemental Analysis: C, 64.36; H, 5.75; Cl, 12.26; N, 12.11; O, 5.53

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
PrCP-7414; PrCP 7414; PrCP7414; Angiotensinase C Inhibitor, Lysosomal Carboxypeptidase C Inhibitor, Lysosomal Pro-X Carboxypeptidase Inhibitor, PCP Inhibitor, Proline Carboxypeptidase Inhibitor, Prolylcarboxypeptidase Inhibitor,
IUPAC/Chemical Name
2-Amino-N-((2S,3S)-3-(biphenyl-4-yl)-1-((2S)-2-(5,6-dichloro-1H-benzimidazol-2-yl)pyrrolidin-1-yl)-1-oxobutan-2-yl)-2-methylpropanamide
InChi Key
PHUWAMRFIHBBMJ-OALGXETFSA-N
InChi Code
InChI=1S/C31H33Cl2N5O2/c1-18(19-11-13-21(14-12-19)20-8-5-4-6-9-20)27(37-30(40)31(2,3)34)29(39)38-15-7-10-26(38)28-35-24-16-22(32)23(33)17-25(24)36-28/h4-6,8-9,11-14,16-18,26-27H,7,10,15,34H2,1-3H3,(H,35,36)(H,37,40)/t18-,26-,27-/m0/s1
SMILES Code
CC(C)(N)C(N[C@@H]([C@H](C1=CC=C(C2=CC=CC=C2)C=C1)C)C(N3[C@H](C4=NC5=CC(Cl)=C(Cl)C=C5N4)CCC3)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Prolylcarboxypeptidase (PrCP) is a serine protease that produces or degrades signaling proteins in several important pathways including the renin-angiotensin system (RAS), kallikrein-kinin system (KKS) and pro-opiomelanocortin (POMC) system. PrCP has the potential to be a therapeutic target for cardiovascular, inflammatory and metabolic diseases.

Preparing Stock Solutions

The following data is based on the product molecular weight 578.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Wu, Z., et al. 2012. Bioorg. Med. Chem. Lett. 22, 1774. Graham, T.H., et al. 2012. Bioorg. Med. Chem. Lett. 22, 658. Zhou, C., et al. 2010. J. Med. Chem. 53, 7251. 1: Graham TH. Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review. Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. doi: 10.1080/13543776.2017.1349104. Epub 2017 Jul 12. Review. PubMed PMID: 28699813. 2: Tabrizian T, Floyd L, Shariat-Madar Z. Altered Prolylcarboxypeptidase Expression and Function in Response to Different Risk Factors of Diabetes. Cardiovasc Hematol Agents Med Chem. 2017;14(3):175-189. doi: 10.2174/1871525714666161229130508. PubMed PMID: 28034286. 3: Graham TH, Shu M, Verras A, Chen Q, Garcia-Calvo M, Li X, Lisnock J, Tong X, Tung EC, Wiltsie J, Hale JJ, Pinto S, Shen DM. Pyrazoles as non-classical bioisosteres in prolylcarboxypeptidase (PrCP) inhibitors. Bioorg Med Chem Lett. 2014 Apr 1;24(7):1657-60. doi: 10.1016/j.bmcl.2014.02.070. Epub 2014 Mar 6. PubMed PMID: 24636945. 4: Debenham JS, Graham TH, Verras A, Zhang Y, Clements MJ, Kuethe JT, Madsen-Duggan C, Liu W, Bhatt UR, Chen D, Chen Q, Garcia-Calvo M, Geissler WM, He H, Li X, Lisnock J, Shen Z, Tong X, Tung EC, Wiltsie J, Xu S, Hale JJ, Pinto S, Shen DM. Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors. Bioorg Med Chem Lett. 2013 Dec 1;23(23):6228-33. doi: 10.1016/j.bmcl.2013.09.094. Epub 2013 Oct 8. PubMed PMID: 24157366. 5: Rabey FM, Gadepalli RS, Diano S, Cheng Q, Tabrizian T, Gailani D, Rimoldi JM, Shariat-Madar Z. Influence of a novel inhibitor (UM8190) of prolylcarboxypeptidase (PRCP) on appetite and thrombosis. Curr Med Chem. 2012;19(24):4194-206. PubMed PMID: 22664251; PubMed Central PMCID: PMC4367813. 6: Zhu L, Carretero OA, Xu J, Wang L, Harding P, Rhaleb NE, Yang JJ, Sumners C, Yang XP. Angiotensin II type 2 receptor-stimulated activation of plasma prekallikrein and bradykinin release: role of SHP-1. Am J Physiol Heart Circ Physiol. 2012 Jun 15;302(12):H2553-9. doi: 10.1152/ajpheart.01157.2011. Epub 2012 Apr 20. PubMed PMID: 22523247; PubMed Central PMCID: PMC3378261. 7: Adams GN, LaRusch GA, Stavrou E, Zhou Y, Nieman MT, Jacobs GH, Cui Y, Lu Y, Jain MK, Mahdi F, Shariat-Madar Z, Okada Y, D'Alecy LG, Schmaier AH. Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. Blood. 2011 Apr 7;117(14):3929-37. doi: 10.1182/blood-2010-11-318527. Epub 2011 Feb 4. PubMed PMID: 21297000; PubMed Central PMCID: PMC3083303. 8: Ngo ML, Mahdi F, Kolte D, Shariat-Madar Z. Upregulation of prolylcarboxypeptidase (PRCP) in lipopolysaccharide (LPS) treated endothelium promotes inflammation. J Inflamm (Lond). 2009 Jan 27;6:3. doi: 10.1186/1476-9255-6-3. PubMed PMID: 19171072; PubMed Central PMCID: PMC2639534. 9: Perkins R, Ngo MD, Mahdi F, Shariat-Madar Z. Identification of lipopolysaccharide binding site on high molecular weight kininogen. Biochem Biophys Res Commun. 2008 Feb 22;366(4):938-43. Epub 2007 Dec 18. PubMed PMID: 18083112. 10: Shariat-Madar Z, Mahdi F, Schmaier AH. Recombinant prolylcarboxypeptidase activates plasma prekallikrein. Blood. 2004 Jun 15;103(12):4554-61. Epub 2004 Mar 2. PubMed PMID: 14996700. 11: Shariat-Madar Z, Mahdi F, Schmaier AH. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem. 2002 May 17;277(20):17962-9. Epub 2002 Feb 5. PubMed PMID: 11830581.